Literature DB >> 22082753

Testosterone and cardiovascular risk in patients with erectile dysfunction.

G Corona1, G Rastrelli, G Balercia, A Sforza, G Forti, M Maggi.   

Abstract

BACKGROUND: The relationship between cardiovascular (CV) diseases (CVD) and testosterone (T) levels in men has not been completely clarified. AIM: To evaluate the association between T levels and CV risk in subjects with erectile dysfunction (ED) and to verify whether their body mass index might (BMI) represents a possible confounder in T-related CV stratification.
MATERIAL AND METHODS: A consecutive series of 2269 male patients attending the Outpatient Clinic for ED was studied. The assessment of CV risk was evaluated using the engine derived from the Progetto Cuore study.
RESULTS: After adjustment and for BMI and associated morbidities, SHBG-bound and -unbound T levels decreased as a function of CV risk assessed thorough Progetto Cuore risk engine. In addition, a higher prevalence of hypogonadism related symptoms and signs was associated with a higher CV risk. Among factors included in the Progetto Cuore risk engine age, total and HDL cholesterol and diabetes were all significantly associated with CV risk-dependent modification of total and calculated free-T levels. When the relationship between SHBG bound and unbound T and CV risk was evaluated as a function of obesity (BMI>30 kg/m(2)), all the aforementioned associations were confirmed only in non obese patients.
CONCLUSIONS: Hypogonadism could be associated either with an increased or reduced CV risk, depending on the characteristics of subjects. Low T observed in obese patients might represent the result of higher CV risk rather than a direct pathogenetic mechanism.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22082753     DOI: 10.3275/8063

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  56 in total

Review 1.  Hypogonadism, ED, metabolic syndrome and obesity: a pathological link supporting cardiovascular diseases.

Authors:  G Corona; E Mannucci; G Forti; M Maggi
Journal:  Int J Androl       Date:  2009-02-10

2.  Diet-induced hypercholesterolemia impaired testicular steroidogenesis in mice through the renin-angiotensin system.

Authors:  José M Martínez-Martos; Marce Arrazola; María D Mayas; María P Carrera-González; María J García; María J Ramírez-Expósito
Journal:  Gen Comp Endocrinol       Date:  2011-04-23       Impact factor: 2.822

3.  Sexual inactivity results in reversible reduction of LH bioavailability.

Authors:  E Carosa; S Benvenga; F Trimarchi; A Lenzi; M Pepe; C Simonelli; E A Jannini
Journal:  Int J Impot Res       Date:  2002-04       Impact factor: 2.896

Review 4.  The cardiac toxicity of anabolic steroids.

Authors:  M L Sullivan; C M Martinez; P Gennis; E J Gallagher
Journal:  Prog Cardiovasc Dis       Date:  1998 Jul-Aug       Impact factor: 8.194

Review 5.  Review: The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship?

Authors:  Henry Völzke; Christian Schwahn; Henri Wallaschofski; Marcus Dörr
Journal:  J Clin Endocrinol Metab       Date:  2007-05-01       Impact factor: 5.958

6.  Increased occurrence of marked elevations of lipoprotein(a) in ageing, hypercholesterolaemic men with low testosterone.

Authors:  Steven A Kaplan; Jianxin Lin; Amy O Johnson-Levonas; Arvind K Shah; Alan G Meehan
Journal:  Aging Male       Date:  2010-03       Impact factor: 5.892

7.  The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men.

Authors:  Chris J Malkin; Peter J Pugh; Richard D Jones; Dheeraj Kapoor; Kevin S Channer; T Hugh Jones
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

Review 8.  Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis.

Authors:  Eric L Ding; Yiqing Song; Vasanti S Malik; Simin Liu
Journal:  JAMA       Date:  2006-03-15       Impact factor: 56.272

9.  Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Authors:  H B Hubert; M Feinleib; P M McNamara; W P Castelli
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

10.  Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction.

Authors:  Giovanni Corona; Matteo Monami; Valentina Boddi; Michela Cameron-Smith; Alessandra D Fisher; Giulia de Vita; Cecilia Melani; Daniela Balzi; Alessandra Sforza; Gianni Forti; Edoardo Mannucci; Mario Maggi
Journal:  J Sex Med       Date:  2010-01-25       Impact factor: 3.802

View more
  5 in total

1.  A critical analysis of testosterone supplementation therapy and cardiovascular risk in elderly men.

Authors:  Jason Scovell; Ranjith Ramasamy; Jason R Kovac
Journal:  Can Urol Assoc J       Date:  2014-05       Impact factor: 1.862

2.  Patient satisfaction with testosterone replacement therapies: the reasons behind the choices.

Authors:  Jason R Kovac; Saneal Rajanahally; Ryan P Smith; Robert M Coward; Dolores J Lamb; Larry I Lipshultz
Journal:  J Sex Med       Date:  2013-11-06       Impact factor: 3.802

3.  Predictors and clinical consequences of starting androgen therapy in men with low testosterone: results from the SIAMO-NOI registry.

Authors:  G Rastrelli; L Giovannini; A E Calogero; D Gianfrilli; E Serra; A Pizzocaro; V A Giagulli; G Motta; G Vancieri; A Sperandio; S Andò; R Selice; G Luca; F Cocchiara; D Canale; M Maggi
Journal:  J Endocrinol Invest       Date:  2016-04-01       Impact factor: 4.256

Review 4.  Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology.

Authors:  A M Isidori; G Balercia; A E Calogero; G Corona; A Ferlin; S Francavilla; D Santi; M Maggi
Journal:  J Endocrinol Invest       Date:  2014-11-11       Impact factor: 4.256

Review 5.  Risks and benefits of late onset hypogonadism treatment: an expert opinion.

Authors:  Giovanni Corona; Linda Vignozzi; Alessandra Sforza; Mario Maggi
Journal:  World J Mens Health       Date:  2013-08-31       Impact factor: 5.400

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.